190 related articles for article (PubMed ID: 28391875)
1. Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variables.
Maki KC; Bobotas G; Dicklin MR; Huebner M; Keane WF
J Clin Lipidol; 2017; 11(1):102-109. PubMed ID: 28391875
[TBL] [Abstract][Full Text] [Related]
2. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
Maki KC; Bays HE; Ballantyne CM; Underberg JA; Kastelein JJP; Johnson JB; Ferguson JJ
J Am Heart Assoc; 2022 Mar; 11(6):e024176. PubMed ID: 35232215
[TBL] [Abstract][Full Text] [Related]
3. Effects of n-3 fatty acid treatment on monocyte phenotypes in humans with hypertriglyceridemia.
Dai Perrard XY; Lian Z; Bobotas G; Dicklin MR; Maki KC; Wu H
J Clin Lipidol; 2017; 11(6):1361-1371. PubMed ID: 28942094
[TBL] [Abstract][Full Text] [Related]
4. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
Oscarsson J; Hurt-Camejo E
Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials of eicosapentaenoic acid (EPA) prescription products for the treatment of hypertriglyceridemia.
Doggrell SA
Expert Opin Pharmacother; 2019 Jul; 20(10):1221-1225. PubMed ID: 31038369
[No Abstract] [Full Text] [Related]
6. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Ballantyne CM; Bays HE; Philip S; Doyle RT; Braeckman RA; Stirtan WG; Soni PN; Juliano RA
Atherosclerosis; 2016 Oct; 253():81-87. PubMed ID: 27596132
[TBL] [Abstract][Full Text] [Related]
7. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
8. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
9. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
11. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) in Women to Lower Triglyceride Levels (Results from the MARINE and ANCHOR Trials).
Mosca L; Ballantyne CM; Bays HE; Guyton JR; Philip S; Doyle RT; Juliano RA
Am J Cardiol; 2017 Feb; 119(3):397-403. PubMed ID: 27939227
[TBL] [Abstract][Full Text] [Related]
13. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).
Bays HE; Braeckman RA; Ballantyne CM; Kastelein JJ; Otvos JD; Stirtan WG; Soni PN
J Clin Lipidol; 2012; 6(6):565-72. PubMed ID: 23312052
[TBL] [Abstract][Full Text] [Related]
14. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
[TBL] [Abstract][Full Text] [Related]
15. A novel, multi-ingredient supplement to manage elevated blood lipids in patients with no evidence of cardiovascular disease: a pilot study.
Hobbs T; Caso R; McMahon D; Nymark M
Altern Ther Health Med; 2014; 20(5):18-23. PubMed ID: 25141367
[TBL] [Abstract][Full Text] [Related]
16. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
[TBL] [Abstract][Full Text] [Related]
17. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
Jacobson TA; Glickstein SB; Rowe JD; Soni PN
J Clin Lipidol; 2012; 6(1):5-18. PubMed ID: 22264569
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Ballantyne CM; Bays HE; Kastelein JJ; Stein E; Isaacsohn JL; Braeckman RA; Soni PN
Am J Cardiol; 2012 Oct; 110(7):984-92. PubMed ID: 22819432
[TBL] [Abstract][Full Text] [Related]
19. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
Brinton EA; Mason RP
Lipids Health Dis; 2017 Jan; 16(1):23. PubMed ID: 28137294
[TBL] [Abstract][Full Text] [Related]
20. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
